Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 08, 2025

SELL
$33.37 - $45.51 $30,900 - $42,142
-926 Reduced 11.24%
7,314 $263,000
Q1 2025

May 09, 2025

BUY
$27.67 - $42.99 $228,000 - $354,237
8,240 New
8,240 $324,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.5B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Thoroughbred Financial Services, LLC Portfolio

Follow Thoroughbred Financial Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thoroughbred Financial Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Thoroughbred Financial Services, LLC with notifications on news.